In both Myf5–Cre/hSS1 and Myf5–Cre/hSS2 lineages, tumor onset, equal between genders, was mainly within skeletal muscle due to Myf5-specific expression in skeletal muscle-committed cells. The gene discussed is MYF5; the disease is neoplasm.